Loading...
Docoh

Xeris Pharmaceuticals (XERS)

Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

XERS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
1 Oct 22
31 Dec 22
Quarter (USD) Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 63.6M 63.6M 63.6M 63.6M 63.6M 63.6M
Cash burn (monthly) 1M 3.24M 8.6M 6.3M 6.67M 5.99M
Cash used (since last report) 15.09M 48.8M 129.52M 94.94M 100.56M 90.19M
Cash remaining 48.51M 14.8M -65.92M -31.34M -36.96M -26.6M
Runway (months of cash) 48.4 4.6 -7.7 -5.0 -5.5 -4.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Oct 21 Persky Marla Stock Option Common Stock Sale back to company Dispose D No No 3.9 11,228 43.79K 0
5 Oct 21 Persky Marla Stock Option Common Stock Sale back to company Dispose D No No 4.68 11,228 52.55K 0
5 Oct 21 Persky Marla Stock Option Common Stock Sale back to company Dispose D No No 10 20,000 200K 0
5 Oct 21 Persky Marla Stock Option Common Stock Sale back to company Dispose D No No 12.5 19,650 245.63K 0
5 Oct 21 John Patrick Shannon Jr Common Stock Sale back to company Dispose D No No 0 193,333 0 0
5 Oct 21 John Patrick Shannon Jr Common Stock Sale back to company Dispose D No No 0 70,496 0 193,333
5 Oct 21 John Patrick Shannon Jr Stock Option Common Stock Sale back to company Dispose D No No 3.94 100,000 394K 0
5 Oct 21 John Patrick Shannon Jr Stock Option Common Stock Sale back to company Dispose D No No 13.88 80,000 1.11M 0
5 Oct 21 John Patrick Shannon Jr Stock Option Common Stock Sale back to company Dispose D No No 12.5 34,977 437.21K 0
5 Oct 21 John Patrick Shannon Jr Stock Option Common Stock Sale back to company Dispose D No No 5.93 28,072 166.47K 0
14.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2 2
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 89.21M 89.21M
Total shares 19.04M 19.04M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Flynn James E 12.44M $56.71M 0.0%
Sessa Capital 6.61M $32.51M 0.0%
Largest transactions Shares Bought/sold Change
Flynn James E 12.44M 0 0.0%
Sessa Capital 6.61M 0 0.0%

Financial report summary

?
Management Discussion
  • We commercially launched Gvoke PFS and Gvoke HypoPen for the treatment of severe hypoglycemia in people with diabetes in November 2019 and July 2020, respectively. Total net sales of Gvoke were $8.8 million and $2.0 million for the three months ended June 30, 2021 and 2020, respectively. Total net sales of Gvoke were $16.9 million and $3.7 million for the six months ended June 30, 2021 and 2020, respectively. Net sales represent gross product sales less estimated allowances for patient copay assistance programs, prompt payment discounts, payor rebates, chargebacks, service fees, and product returns, all of which are recorded at the time of sale to the pharmaceutical wholesaler or other customer. We apply significant judgments and estimates in determining some of these allowances. If actual results differ from our estimates, we make adjustments to these allowances in the period in which the actual results or updates to estimates become known. During the three months ended March 31, 2021, we made adjustments to rebate and patient assistance copay accruals which were recorded in prior years based on actual claims experience to date, which increased revenue by $0.9 million. During the three months ended June 30, 2021, we made adjustments to the accrued returns reserve related to prior years' sales based on actual returns experience, which decreased revenue by $0.9 million. For the six months ended June 30, 2021, these adjustments offset and together had no impact on net sales.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absence, abstained, addressed, antitrust, Appendix, Biopharma, Cadillac, certiorari, combat, constitutionality, consummate, consummated, consummation, contemplated, conventional, custody, CVR, director, dismissed, distinct, divestiture, Dublin, EDPB, EIH, entry, enumerated, era, exacerbated, examine, excessive, excise, falsifying, framework, FTC, gouging, HoldCo, HSR, impossible, Inspector, instated, instructed, Ireland, Irish, issuer, Jeffrey, London, MergerSub, momentum, mutually, nurse, Panel, pendency, permission, Phase, Pieper, plc, preapproval, preempted, proceed, reexamining, Registrar, sanction, settleable, shareholder, Sherman, solubility, stability, Strongbridge, supplementary, Switzerland, Territory, tied, timeframe, tracing, trick, unnecessary, waiting, waiver, week, wholly, worth, writ
Removed: aimed, applying, Barry, Deutsch, intraperiod, losing, lowering

Patents

Utility
Stable formulations for parenteral injection of small molecule drugs
20 Sep 22
Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.
Utility
Precipitation Resistant Small Molecule Drug Formulations
31 Mar 22
Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation.
Utility
Stable Sustained Release Therapeutic Compositions In Aprotic Polar Solvents and Methods of Manufacturing the Same
30 Dec 21
The present invention relates to the use of aprotic polar solvents and an ionization stabilizing agent to prepare storage stable sustained release therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be administered to patients suffering from or predisposed to a variety of physical conditions or disorders, notably hypoglycemia.
Utility
Stable Formulations for Parenteral Injection of Peptide Drugs
14 Oct 21
Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided.
Utility
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
28 Sep 21
This disclosure includes syringes, kits containing the same, and related methods.